The Short Answer
Inspire Medical (INSP) has a qualitative business verdict that is HALAL, but the latest filing-based liquidity screen fails. Inspire develops and commercializes minimally-invasive solutions for patients with obstructive sleep apnea (OSA).
Medical-device manufacturing and implantable-neurostimulation-therapy development are generally permissible at the activity level. The March 31, 2026 filing reports no debt, but cash plus debt securities are 43.86% of assets, above the examined 33.333% limits.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0 / 911.376
399.716 / 911.376
204.02 / 911.376
3.741 / 204.583
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 43.86%, above the examined 33.333% limit; debt/assets is 0.00%, receivables-plus-cash/assets is 22.39% and investment income is 1.83% of revenue.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 43.86%, above the examined MSCI 33.33% total-assets limit; debt and receivables-plus-cash pass.
- Financial
- Fails
- Overall
- Fails
Identifiable liquidity/assets is 43.86%, above the examined Malaysia 33% limit; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; liquidity failure is independently documented.
Business-activity disclosure
Inspire Medical Systems develops and sells an implantable neurostimulation system for obstructive sleep apnea. Medical-device manufacturing and patient-therapy activity are generally permissible, but the filing does not provide a universal prohibited-revenue numerator.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; clinical, reimbursement and downstream use remain qualitative.
Purification
The filing combines interest and dividend investment income; ZakatInvest uses the $3.741 million line as a conservative upper bound and does not prescribe a fixed purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Inspire Medical Systems' March 31, 2026 Form 10-Q.
- No interest-bearing debt is reported at period end; operating leases are excluded.
- Cash is $98.932 million, short- and long-term debt securities total $300.784 million, and accounts receivable, net is $105.088 million.
- First-quarter revenue is $204.583 million and investment income (interest and dividends) is $3.741 million, shown as a conservative upper bound rather than a purification prescription.
- The implantable neurostimulation medical-device business is retained as qualitative activity analysis; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
Inspire's Business Activity
Inspire Medical Systems makes:
- The Inspire system: An implantable neurostimulation device that delivers hypoglossal-nerve stimulation to keep the airway open during sleep
- Implant components: The surgical-implant hardware and patient remote
- Support technology: Physician-and-patient support systems
This is a healthcare and medical-device business addressing a genuine medical need. This is permissible at the activity level.
Concerns to Be Aware Of
1. Large Investment Portfolio
Inspire holds a large cash-and-debt-securities position. The filing combines interest and dividend investment income; ZakatInvest uses that line as a conservative upper bound and does not prescribe a fixed purification percentage.
2. Reimbursement & Competition
The business depends on reimbursement, regulatory clearances, and physician-adoption, and faces emerging competition (including from new device entrants and from pharmaceutical OSA-and-weight-loss therapies). These are business and regulatory considerations rather than Sharia screen concerns.
3. Concentration & Valuation
Revenue is concentrated in a single product line, and the stock frequently trades at a premium growth valuation and can be volatile. These are business-concentration and valuation considerations rather than Sharia screen concerns.
Filing-Based Ratios (March 31, 2026)
Using the latest Inspire Medical Systems Form 10-Q (USD millions):
- Debt / total assets: 0.00%
- Cash + securities / total assets: 43.86% — above the examined 33.333% limits
- Receivables + cash / total assets: 22.39%
- Investment income / revenue: 1.83% conservative upper bound
Methodology Interpretation
These are ZakatInvest calculations from the cited filing, not claims of current index membership or an official scholar ruling:
- FTSE-style: Fails the liquidity ratio.
- MSCI-style: Fails the liquidity ratio.
- Malaysia-style: Fails the identifiable-liquidity ratio.
Bottom Line
Inspire Medical (INSP) has a generally permissible medical-device business and no reported interest-bearing debt, but the latest filing-based liquidity ratio fails the examined asset-based methods. That is a failed quantitative screen, not a universal religious ruling; investors should review the next filing and consult their preferred methodology.
For Muslim investors seeking medical-device exposure, INSP sits alongside other halal-screened names like Boston Scientific (BSX) and Edwards Lifesciences (EW).
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →